Approved Antiviral Drugs for Hepatitis C Virus (HCV) Treatment

boceprevir (BOC)  an NS3/4A protease inhibitor (PI); approved in 2011
peginterferon alfa (PEG)  a synthetic version of a substance normally produced in the body to fight infection; approved in 2001
ribavirin (RBV)  a nucleoside analogue, used in combination with at least 1 other drug; approved in 2001
telaprevir (TVR)  an NS3/4A PI; approved in 2011

Investigational Antiviral Drugs for HCV Treatment

This list is not necessarily comprehensive and is intended as an aid in following course presentations.

In Phase III Testing:

ABT-267  an NS5A inhibitor
ABT-333  an NS5B polymerase inhibitor
ABT-450/r  a ritonavir-boosted (/r) PI
asunaprevir  formerly BMS-650032; an NS3 PI
daclatasvir  formerly BMS-790052; an NS5A inhibitor
deleobuvir  formerly BI 207127; an NS5B polymerase inhibitor
faldaprevir  formerly BI 201335; an NS3/4A PI
ledipasvir  formerly GS-5885; an NS5A inhibitor
mericitabine  an NS5B polymerase inhibitor
narlaprevir  formerly SCH 900518; an NS3/NS4A inhibitor
simeprevir  formerly TMC435; an NS3/4A PI
sofosbuvir  formerly GS-7977; an NS5B polymerase inhibitor
vaniprevir  formerly MK-7009; an NS3/4A PI

In Phase II Testing:

BMS-791325  an NS5B polymerase inhibitor
danoprevir  formerly RG7227; an NS3/4A PI
VX-135  formerly ALS-2200; an NS5B polymerase inhibitor

Organizations, Conferences, and Legislation

AASLD  American Association for the Study of Liver Diseases
ASM  American Society for Microbiology
CROI  Conference on Retroviruses and Opportunistic Infections
DSMB  Data and Safety Monitoring Board
DHHS  Department of Health and Human Services
EASL  European Association for the Study of the Liver
IAS–USA  International Antiviral Society–USA
ICAAC  Interscience Conference on Antimicrobial Agents and Chemotherapy
NIH  National Institutes of Health
General Medical Terms

AE  adverse effect
AFP  alpha-fetoprotein
AKR  aldo-keto reductase
ALT  alanine aminotransferase
ART  antiretroviral therapy
ARV  antiretroviral
AST  aspartate aminotransferase
AUC  area under the curve
BLD  below the limit of detection
BLQ  below the limit of quantification
BMI  body mass index
cEVR  complete early virologic response
CC, CT, TT  IL28B gene polymorphisms
COPD  Chronic Obstructive Pulmonary Disease
CP or CTP Score  Child-Pugh Score or Child-Turcotte-Pugh Score
CSF  cerebrospinal fluid
DAA  direct-acting antiviral
DCP  des-gamma-carboxy-prothrombin
EGD  esophagogastroduodenoscopy
EIA  enzyme immunoassay
ELISA  enzyme-linked immunosorbent assay
EPO  erythropoietin
EOT  end of treatment
eRVR  extended rapid virologic response
ESLD  end-stage liver disease
ETR  end-of-treatment response
EVR  early virologic response
FIB-4  a test for hepatic fibrosis
Forns index  a test for hepatic fibrosis
GGT  gamma-glutamyl transferase
GT or gt  genotype
HA  hyaluronic acid
HAI  histological activity index; used to determine stage of liver disease
HbcAb  hepatitis B core antibody
HbcAg  hepatitis B core antigen
HbeAb  hepatitis B “e” antibody
HbeAg  hepatitis B “e” antigen
HBIG  hepatitis B immune globulin
HbsAb  hepatitis B surface antibody
HbsAg  hepatitis B surface antigen
HCC  hepatocellular carcinoma
HE  hepatic encephalopathy
HPS  hepatorenal syndrome
HVPG  hepatic venous pressure gradient
IFN  interferon alfa
IgG  immunoglobulin G
IL28B  a genotype that can help indicate likelihood of HCV treatment response to interferon
INR  International Normalized Ratio
IRES  internal ribosome entry segment
ISG  interferon-stimulated gene
LFT  liver function test
MELD  model for end-stage liver disease; a scoring system for assessing the severity of chronic liver disease
Metavir  a scoring system used to determine stage of liver disease
OLT  orthotopic liver transplantation
pEVR  partial early virologic response
P-gp  P-glycoprotein
PI  protease inhibitor
PR or P/R  peginterferon alfa and ribavirin
PT  prothrombin time
RAV  resistance-associated variant
RGT  response-guided therapy
RVR  rapid virologic response
SBP  spontaneous bacterial peritonitis
SVR  sustained virologic response
TIMP  tissue inhibitor of metalloproteinase
VL  viral load

**Opportunistic Infections (OIs)**
HAV  hepatitis A virus
HBV  hepatitis B virus
HCV  hepatitis C virus
HDV  hepatitis D virus
HEV  hepatitis E virus
HIV  human immunodeficiency virus